IL6 and hepatocellular carcinoma: Experimental studies have shown that the self-emulsifying nanophase of XCHT can be targeted and delivered to the liver, significantly reducing ALT levels in a CCl4-induced hepatic fibrosis-HCC mouse model, as well as alleviating chronic inflammation and decreasing collagen deposition by inhibiting TNF-α and IL-6 secretion [160, 161].